761440-64-6Relevant articles and documents
Synthesis method of Brigatinib intermediate
-
Paragraph 0034-0038; 0044-0051, (2021/06/26)
The invention discloses a synthesis method of a Brigatinib intermediate. The Brigatinib intermediate is 2-methoxy-4-(4-(4-methyl piperazine-1-yl) piperidine-1-yl) aniline (I). The synthesis method comprises the following steps: taking 5-fluoro-2-nitroanis
Substituted diaminopyrimidine compound
-
Paragraph 0229-0234, (2019/07/04)
The present invention provides a substituted diaminopyrimidine compound represented by a formula (I), or a pharmaceutically acceptable salt, a crystal form, a prodrug, a metabolite, a hydrate, a solvate, a stereoisomer or an isotope derivative thereof, as well as a pharmaceutical composition and uses thereof. The compound provided by the invention can be used for treating ALK-mediated related diseases, such as non-small cell lung cancer, breast cancer, neural tumor, esophageal cancer, soft tissue cancer, lymphoma and leukemia.
2,4-dibasic miazines compound
-
Paragraph 0264; 0265; 0266; 0267; 0268, (2017/08/29)
The invention belongs to the field of medical chemistry, relates to a 2,4-dibasic miazines compound and specifically relates to a compound shown as formula (I) or a pharmaceutically acceptable salt thereof, a drug compound thereof and an application thereof in treating EGFR or/and ALK mediated diseases.